"The pharmacist remains a very important member of the healthcare team that has the ability to explain to the patient the differences between the biologic and the biosimilar. It is the pharmacist–patient relationship that will assist the patient in making the best decisions to obtain the optimal clinical outcome," said Larry D. Wagenknecht, PharmD, FMPA, FAPhA, CEO of the Michigan Pharmacists Association.
Recently, Michigan Governor, Republican Rick Snyder, signed into effect legislation that creates a pathway for the substitution of FDA-designated interchangeable biosimilars for their reference products at the pharmacy level. The Center for Biosimilars® interviewed Larry D. Wagenknecht, PharmD, FMPA, FAPhA, CEO of the Michigan Pharmacists Association on his organization’s stance on the new law.
When asked if his organization supported the bill, Wagenknecht said in an email, “The Michigan Pharmacists Association did end up supporting the legislation after some changes were made to the prescriber notification section of the bill.” He added that the Association wants to ensure that the law does not create any undue barriers in providing patients with access to the best options that will treat their conditions.
Currently, there are no FDA-approved interchangeable biosimilars, nor has any drug maker sought such a designation for a biosimilar product. With respect to the rationale for passing legislation dealing with interchangeable biosimilars now, Wagenknecht said the move was in preparation for the future: “The benefit of passing the bill now [March 2018] is minimal since the opportunity for substitution of a biosimilar really isn’t an option today. However, with the medications in the biosimilar pipeline, there will likely be opportunities in the coming years."
It remains unclear whether legislation passed concerning the substitution of interchangeable biosimilars, which has been passed or considered in numerous other states, such as South Dakota and Wisconsin in the early months of this year, will have any impact on uptake amongst prescribers of biosimilar medicines.
Wagenknecht said, “[The prescribing of biosimilars] is very difficult to predict. Biosimilar medications tend to treat more complicated medical conditions, so having a law on the books is not going to increase the use of biosimilar medications. The economics of healthcare will push for the use of biosimilars once they are available.”
Asked if members of his organization dispense biosimilars now, Wagenknecht said, “Our members do dispense biologics, and since the opportunity of dispensing biosimilars is not prevalent, we really don’t know how patients are going to respond. The pharmacist remains a very important member of the healthcare team that has the ability to explain to the patient the differences between the biologic and the biosimilar. It is the pharmacist—patient relationship that will assist the patient in making the best decisions to obtain the optimal clinical outcome.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.